StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
IRIX$1.11+5.71%
Fair $1.11+0.0%

IRIX

IRIDEX Corporation

Healthcare / Medical DevicesNasdaqCM

$1.11

+0.06 (+5.71%)

Fairly Valued+0.0%Fair Value $1.11Fund rank 26/100 · Data gapFallback financials|
SA 14/F
F-Score: 2/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 25%

FCF escenarios

weak_data · normalized FCF $-2.3M · quality 53.0/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 36/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

14/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 15Warnings: 1unknown: 15
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -90.1%, below the 5% threshold
Thesis & Journal · IRIXLocal privado en este navegador · IRIDEX Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$19M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-90.1%

↓

Gross Margin

36.5%

↓

Debt/Equity

N/A

•
52-Week Range$1
$1$2

TradingView lightweight chart

IRIX price, volumen y niveles de valoración

Último $1.110Periodo -87.1%
Fair value: $1.110

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2010–2026 · 16 años de histórico normalizado

Revenue CAGR

+3.4%

FCF CAGR

—

FCF margin

-4.3%

FCF / Net income

0.51x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $52.7M · net income $-4.4M · FCF $-2.3M

2010-FY → 2026-FY

Gross margin

36.5%-13.3% pts

Operating margin

-4.9%-8.8% pts

Net margin

-8.4%-16.8% pts

FCF margin

-4.3%-13.4% pts
MetricTTM
2026
2025
2024
2023
2022
2021
2019
2018
2017
2016
2015
2013
2012
2011
2010
Income Statement
Revenue$52.7M$52.7M$52.7M$48.7M$51.9M$57.0M$36.3M$43.4M$42.6M$41.6M$46.2M$42.8M$38.3M$33.9M$33.2M$31.0M
Net Income$-4.4M$-4.4M$-4.4M$-8.9M$-9.6M$-7.5M$-6.3M$-8.8M$-12.8M$-12.9M$-11.7M$10.0M$2.2M$1.4M$2.6M$2.6M
EBITDA$-2.0M$-2.0M$-1.0M$-6.9M$-8.0M$-6.2M$-6.1M$-8.3M$-12.1M$-12.0M$-1.9M$3.0M$3.1M$-433000.00$2.3M$1.7M
EPS-0.26-0.26-0.26-0.54-0.59-0.47-0.46-0.64-1.05-1.11-1.150.970.220.160.26—
Gross Margin36.5%36.5%36.5%40.1%42.0%44.5%42.8%41.3%41.0%37.3%45.1%50.0%48.6%48.3%49.1%49.8%
Operating Margin-4.9%-4.9%-4.9%-17.1%-19.3%-13.2%-18.1%-20.7%-30.2%-31.0%-5.6%6.0%6.9%-2.5%5.8%4.0%
Net Margin-8.4%-8.4%-8.4%-18.3%-18.5%-13.2%-17.4%-20.3%-30.1%-30.9%-25.4%23.4%5.8%4.2%7.9%8.3%
Balance Sheet
Debt/Equity——0.922.210.290.100.07—————————
Current Ratio——1.92—————————————
Cash Flow
Free Cash Flow$-2.3M$-2.3M$-2.3M$-7.3M$-6.9M$-9.8M$-3.3M$-8.0M$-10.5M$-4.1M—$3.4M$387000.00$-1.5M$2.0M$2.8M
Returns
ROE-90.1%-90.1%-90.1%-424.9%-100.5%-43.8%-36.4%-38.8%-42.8%-42.2%-29.9%29.8%8.6%6.6%11.6%17.2%
Valuation
P/B——3.8213.884.962.03——————————
Growth & Yield
Revenue Growth8.2%8.2%8.2%-6.2%-9.0%—-16.3%2.0%2.4%-9.9%7.8%11.9%13.0%2.1%6.9%—
EPS Growth51.9%51.9%51.9%8.5%-25.5%—28.1%39.0%5.4%3.5%-218.6%340.9%37.5%-38.5%——

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +11.0%

Total return

+11.0%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.26 → -0.26

Residual

+11.0%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+11.0%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.